Bloomberg News
@Bloomberg-News·2.8M subscribers·40.1K videos
Pfizer CEO says Covid-19 Vaccine 'Now in FDA's Hands'
Posted
November 20, 2020
Views
746
Likes
8
Comments
5
Engagement
1.74%
November 20, 2020
746
8
5
1.74%
Every word spoken in this episode is indexed. Type any phrase to jump straight to the moment it was said.
Type any word or phrase that may have been spoken. Click a result to seek the player to that exact moment.
Try a name, a topic, or a quoted line
Episode Timeline
Every episode in order around the one you’re watching — click any card and the page flips straight to it.
0:43Now PlayingThe CEO of Pfizer speaks after asking U.S. regulators to allow emergency use of its vaccine in the U.S. This step will start the clock on a process that could bring limited first shots as early as next month and eventually an end to the pandemic -- but not until after a long, hard winter.
"It is with great pride and joy and even a little relief, but I can say that our request for emergency use authorization for our covid-19 vaccine is now in the FDA hands," said Albert Bourla, CEO of Pfizer.
Earlier this week, Pfizer and its German partner BioNTech announced that its vaccine appears 95% effective at preventing mild to severe COVID-19 disease in a large, ongoing study.
The companies said that protection plus a good safety record means the vaccine should qualify for emergency use authorization, something the Food and Drug Administration can grant before the final testing is fully complete. With the coronavirus surging around the U.S. and the world, the pressure is on for regulators to make a speedy decision.
Bourla also said they are working in other parts of the world.
"The journey is not yet complete. In addition to today's submissions to the FDA, we have already initiated rolling submissions in Australia, Canada, Europe, Japan and the UK, and we plan to submit immediately to other regulatory authorities around the world," he said.
The FDA and its independent advisers are expected to debate in the coming weeks if the shots are ready. If so, still another government group will have to decide how the initial limited supplies are rationed out to anxiously awaiting Americans.
"Based on current projections, we expect to produce globally up to 50 million doses in 2020 and up to one point three billion doses by the end of 2021," said Bourla.
Recipients will need two doses, three weeks apart.
Subscribe to our YouTube channel
Bloomberg Quicktake brings you live global news and original shows spanning business, technology, politics and culture. Make sense of the stories changing your business and your world.
To watch complete coverage on Bloomberg Quicktake 24/7, visit or watch on Apple TV, Roku, Samsung Smart TV, Fire TV and Android TV on the Bloomberg app.
Connect with us on…
Breaking News on YouTube
Sentinel Indexing in Progress
Metadata and chapters are available. Claim extraction for this episode is pending.
All video content is delivered via YouTube embedded players in accordance with the YouTube Terms of Service. Sentinel provides research tools that promote discovery and accountability across political media.
